Non-alcoholic fatty liver disease classification: Difference between revisions
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) |
||
| Line 38: | Line 38: | ||
====NAFLD Activity Score <ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref name="urlTransplant Pathology Internet Services">{{cite web |url=http://tpis.upmc.com/changebody.cfm?url=/tpis/schema/NAFLD2006.jsp |title=Transplant Pathology Internet Services |format= |work= |accessdate=}}</ref>==== | ====NAFLD Activity Score <ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref name="urlTransplant Pathology Internet Services">{{cite web |url=http://tpis.upmc.com/changebody.cfm?url=/tpis/schema/NAFLD2006.jsp |title=Transplant Pathology Internet Services |format= |work= |accessdate=}}</ref>==== | ||
NAFLD activity score is employed for grading steatohepatitis of NASH. NAS represents the sum of scores for [[steatosis]], lobular [[inflammation]], and ballooning. | NAFLD activity score is employed for grading steatohepatitis of NASH. NAS represents the sum of scores for [[steatosis]], lobular [[inflammation]], and ballooning. | ||
{| class="wikitable" | |||
!Component | |||
!Range | |||
!Score | |||
|- | |||
| rowspan="4" |Steatosis | |||
|<5% | |||
|0 | |||
|- | |||
|5-33% | |||
|1 | |||
|- | |||
|34-66% | |||
|2 | |||
|- | |||
|>66% | |||
|3 | |||
|- | |||
| rowspan="4" |Lobular Inflammation | |||
|None | |||
|0 | |||
|- | |||
|<2 focci | |||
|1 | |||
|- | |||
|2-4 | |||
|2 | |||
|- | |||
|>4 | |||
|3 | |||
|- | |||
| rowspan="3" |Hepatocyte Balloning | |||
|None | |||
|0 | |||
|- | |||
|Few ballooned cells | |||
|1 | |||
|- | |||
|Many ballooned cells | |||
|2 | |||
|- | |||
| rowspan="3" |Interpretation | |||
|0-2 | |||
|Non-diagnostic | |||
|- | |||
|3-4 | |||
|Borderline | |||
|- | |||
|5-8 | |||
|Diagnostic | |||
|} | |||
{| class="wikitable" | {| class="wikitable" | ||
!Steatosis | !Steatosis | ||
Revision as of 17:16, 21 December 2017
|
Non-Alcoholic Fatty Liver Disease Microchapters |
|
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case studies |
|
Non-alcoholic fatty liver disease classification On the Web |
|
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease classification |
|
Non-alcoholic fatty liver disease classification in the news |
|
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
|
Risk calculators and risk factors for Non-alcoholic fatty liver disease classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Non-alcoholic fatty liver disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.
Classification
Non-alcoholic fatty liver disease may be classified based on clinical presentation into non-alcoholic fatty liver and non-alcoholic steatohepatitis.[1][2][3]
| Based on clinical presentation | |
|---|---|
| Non-alcoholic fatty aliver | Non-alcoholic steatohepatitis |
|
|
|
|
| Based on histopathology | |
| |
| |
NAFLD Activity Score [4][5]
NAFLD activity score is employed for grading steatohepatitis of NASH. NAS represents the sum of scores for steatosis, lobular inflammation, and ballooning.
| Component | Range | Score |
|---|---|---|
| Steatosis | <5% | 0 |
| 5-33% | 1 | |
| 34-66% | 2 | |
| >66% | 3 | |
| Lobular Inflammation | None | 0 |
| <2 focci | 1 | |
| 2-4 | 2 | |
| >4 | 3 | |
| Hepatocyte Balloning | None | 0 |
| Few ballooned cells | 1 | |
| Many ballooned cells | 2 | |
| Interpretation | 0-2 | Non-diagnostic |
| 3-4 | Borderline | |
| 5-8 | Diagnostic |
| Steatosis | S-Score |
|---|---|
| <5%† | 0 |
| 5–33% | 1 |
| 34–66% | 2 |
| >66% | 3 |
| Lobular Inflammation | L-Score |
| None♥ | 0 |
| <2 foci | 1 |
| 2–4 foci | 2 |
| >4 foci | 3 |
| Hepatocyte Balloning | B-Score |
| None | 0 |
| Few ballooned cells¥ | 1 |
| Many ballooned cells₩ | 2 |
| Interpretation
Ranges from 0-8 |
|
References
- ↑ Hashimoto E, Tokushige K, Ludwig J (2015). "Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges". Hepatol Res. 45 (1): 20–8. doi:10.1111/hepr.12333. PMID 24661406.
- ↑ Cobbina E, Akhlaghi F (2017). "Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters". Drug Metab Rev. 49 (2): 197–211. doi:10.1080/03602532.2017.1293683. PMC 5576152. PMID 28303724.
- ↑ Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL (2014). "Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease". Anal Cell Pathol (Amst). 2014: 526979. doi:10.1155/2014/526979. PMC 4333905. PMID 25763333.
- ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
- ↑ "Transplant Pathology Internet Services".